Literature DB >> 8241207

A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation.

J D Cooper1, M Billingham, T Egan, M I Hertz, T Higenbottam, J Lynch, J Mauer, I Paradis, G A Patterson, C Smith.   

Abstract

A clinically applicable, standardized method for assessing functional results after lung transplantation is required to evaluate factors that may affect long-term outcome, to permit comparison of results from different centers, and to evaluate results of clinical trials. An ad hoc working group was established under the auspices of the International Society for Heart and Lung Transplantation for the purpose of developing such a clinically applicable system. Chronic allograft dysfunction is often associated with pathologic findings of obliterative bronchiolitis, the cause of which has not been defined. Physiologically, such dysfunction is associated with obstructive airways disease. The group concluded that the forced expiratory volume in 1 second was the most reliable and consistent indicator of graft dysfunction, excluding other identifiable causes. The term bronchiolitis obliterans syndrome was adopted to describe such dysfunction, recognizing that there may or may not be pathologic evidence of bronchiolitis obliterans present. Four stages of bronchiolitis obliterans syndrome were defined, each with two subcategories to indicate whether pathologic evidence of obliterative bronchiolitis had been identified. This working formulation will require reappraisal in the future to reassess its practical application and to make such adjustments as may seem appropriate.

Entities:  

Mesh:

Year:  1993        PMID: 8241207

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  103 in total

1.  Long-term exposure of chemokine CXCL10 causes bronchiolitis-like inflammation.

Authors:  Dianhua Jiang; Jiurong Liang; Rishu Guo; Ting Xie; Francine L Kelly; Tereza Martinu; Ting Yang; Alysia K Lovgren; Jessica Chia; Ningshan Liu; Yoosun Jung; Scott M Palmer; Paul W Noble
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-08       Impact factor: 6.914

2.  (3)He-MRI in follow-up of lung transplant recipients.

Authors:  Klaus Kurt Gast; Julia Zaporozhan; Sebastian Ley; Alexander Biedermann; Frank Knitz; Balthasar Eberle; Joerg Schmiedeskamp; Claus-Peter Heussel; Eckhard Mayer; Wolfgang Günter Schreiber; Manfred Thelen; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2003-10-16       Impact factor: 5.315

3.  Lung transplant for interstitial lung disease: outcomes for single versus bilateral lung transplantation.

Authors:  Nilto C De Oliveira; Satoru Osaki; James Maloney; Richard D Cornwell; Keith C Meyer
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-12-16

4.  Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients.

Authors:  C Ashley Finlen Copeland; Laurie D Snyder; David W Zaas; W Jackson Turbyfill; W Austin Davis; Scott M Palmer
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

Review 5.  Gastroesophageal reflux and altered motility in lung transplant rejection.

Authors:  J M Castor; R K Wood; A J Muir; S M Palmer; R A Shimpi
Journal:  Neurogastroenterol Motil       Date:  2010-05-26       Impact factor: 3.598

Review 6.  Inflammation in lung transplantation for CF. Immunosuppression and modulation of inflammation.

Authors:  George B Mallory
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

7.  Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation.

Authors:  Aric L Gregson; Xiaoyan Wang; S Sam Weigt; Vyacheslav Palchevskiy; Joseph P Lynch; David J Ross; Bernard M Kubak; Rajan Saggar; Michael C Fishbein; Abbas Ardehali; Gang Li; Robert Elashoff; John A Belperio
Journal:  Am J Respir Crit Care Med       Date:  2013-01-17       Impact factor: 21.405

8.  Cross sectional study of exhaled nitric oxide levels following lung transplantation.

Authors:  A J Fisher; E Gabbay; T Small; S Doig; J H Dark; P A Corris
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

9.  Lymph Node Stromal Fiber ER-TR7 Modulates CD4+ T Cell Lymph Node Trafficking and Transplant Tolerance.

Authors:  Bryna E Burrell; Kristi J Warren; Yumi Nakayama; Daiki Iwami; C Colin Brinkman; Jonathan S Bromberg
Journal:  Transplantation       Date:  2015-06       Impact factor: 4.939

10.  Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy.

Authors:  Kenneth R McCurry; Aldo Iacono; Adrianna Zeevi; Samuel Yousem; Alin Girnita; Shahid Husain; Diana Zaldonis; Bruce Johnson; Brack G Hattler; Thomas E Starzl
Journal:  J Thorac Cardiovasc Surg       Date:  2005-08       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.